Impact of single immunosuppressive drug withdrawal on lymphocyte immunoreactivity

Journal of Surgical Research

Volumn 188, Issue 1, 2014, Pages 309-315

  Verma, Meenakshi ^a   Awdishu, Linda ^b   Lane, James ^b   Park, Ken ^a   Bahur, Bayda ^a   Lwin, Wint ^a   Mcgee, Halvor ^a,c   Steiner, Robert ^b   Finn, Patricia ^a,c   Perkins, David ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Immunosuppression; Rejection; Sirolimus; Tacrolimus; Transplantation

Indexed keywords

ADENOSINE TRIPHOSPHATE; BROXURIDINE; CREATININE; INTERLEUKIN 17; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG RESPONSE; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; MORNING DOSAGE; NORMAL HUMAN; OPTIMAL DRUG DOSE; ORAL GLUCOSE TOLERANCE TEST; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CREATININE RATIO; PROTEIN URINE LEVEL; SINGLE DRUG DOSE; T LYMPHOCYTE; URINALYSIS; YOUNG ADULT;

IMMUNOSUPPRESSION; REJECTION; SIROLIMUS; TACROLIMUS; TRANSPLANTATION;

ADULT; CROSS-OVER STUDIES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; LYMPHOCYTES; MALE; MIDDLE AGED; SIROLIMUS; TACROLIMUS; YOUNG ADULT;

EID: 84897447055     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.11.1085     Document Type: Article

References (18)

1. M. Naesens, D.R. Kuypers, and M. Sarwal Calcineurin inhibitor nephrotoxicity Clin J Am Soc Nephrol 4 2009 481
2. L. Rostaing, P. Massari, V.D. Garcia, E. Mancilla-Urrea, G. Nainan, and M. del Carmen Rial et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: A randomized phase II study Clin J Am Soc Nephrol 6 2011 430
3. C. Sommerer, P. Schnitzler, S. Meuer, M. Zeier, and T. Giese Pharmacodynamic monitoring of cyclosporin a reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older Ther Drug Monit 33 2011 694
4. S. De Geest, L. Borgermans, H. Gemoets, I. Abraham, H. Vlaminck, and G. Evers et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients Transplantation 59 1995 340
5. J. Sellares, D.G. de Freitas, M. Mengel, J. Reeve, G. Einecke, and B. Sis et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence Am J Transplant 12 2012 388
6. S.M. Pollock-Barziv, Y. Finkelstein, C. Manlhiot, A.I. Dipchand, D. Hebert, and V.L. Ng, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children Pediatr transplant 14 2010 968
7. G.I. Snell, B.J. Levvey, L. Zheng, M. Bailey, B. Orsida, and T.J. Williams et al. Interleukin-17 and airway inflammation: A longitudinal airway biopsy study after lung transplantation J Heart Lung Transpl 26 2007 669
8. C.T. Weaver, L.E. Harrington, P.R. Mangan, M. Gavrieli, and K.M. Murphy Th17: An effector CD4 T cell lineage with regulatory T cell ties Immunity 24 2006 677
9. S.Q. Crome, A.Y. Wang, and M.K. Levings Translational mini-review series on Th17 cells: Function and regulation of human T helper 17 cells in health and disease Clin Exp Immunol 159 2010 109
10. T. Weber, D. Abendroth, and H. Schelzig Rapamycin rescue therapy in patients after kidney transplantation: First clinical experience Transpl Int 18 2005 151
11. P.F. Halloran Immunosuppressive drugs for kidney transplantation The New Engl j med 351 2004 2715
12. M.D. Denton, C.C. Magee, and M.H. Sayegh Immunosuppressive strategies in transplantation Lancet 353 1999 1083
13. A. Cataneo-Davila, J. Zuniga-Varga, R. Correa-Rotter, and J. Alberu Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination Transpl Proc 41 2009 4138
14. R. Ireland Transplantation: Does switching to a CNI-free regimen reduce cancer risk? Nat Rev Nephrol 7 2011 548
15. M.B. Prendergast, and R.S. Gaston, Optimizing medication adherence: An ongoing opportunity to improve outcomes after kidney transplantation Clin J Am Soc Nephrol 5 2010 1305
16. S. Greenstein, and B. Siegal Odds probabilities of compliance and noncompliance in patients with a functioning renal transplant: A multicenter study Transpl Proc 31 1999 280
17. C. Hartel, N. Schumacher, L. Fricke, B. Ebel, H. Kirchner, and M. Muller-Steinhardt Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): Impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect Clin chem 50 2004 141
18. E.A. El-Safa, S. Fredericks, I. MacPhee, D.W. Holt, and A. Johnston Paradoxical response to tacrolimus assessed by interleukin-2 gene expression Transplant proc 38 2006 3327